

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* <u>Randhawa Simrat</u>			2. Issuer Name and Ticker or Trading Symbol <u>Dianthus Therapeutics, Inc. /DE/ [DNTH]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) EVP, Head of R&D		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 06/01/2026					
C/O DIANTHUS THERAPEUTICS, INC. 7 TIMES SQUARE, 43RD FLOOR			4. If Amendment, Date of Original Filed (Month/Day/Year)			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		
(Street)	(City)	(State)	(Zip)					
NEW YORK	NY		10036					

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	06/01/2026		M ⁽¹⁾		3,998	A	\$8.44	7,998	D	
Common Stock	06/01/2026		M ⁽¹⁾		6,908	A	\$17.88	14,906	D	
Common Stock	06/01/2026		M ⁽¹⁾		6,249	A	\$21.77	21,155	D	
Common Stock	06/01/2026		M ⁽¹⁾		9,375	A	\$22.07	30,530	D	
Common Stock	06/01/2026		S ⁽¹⁾		5,428	D	\$89.72 ⁽²⁾	25,102	D	
Common Stock	06/01/2026		S ⁽¹⁾		16,943	D	\$90.72 ⁽³⁾	8,159	D	
Common Stock	06/01/2026		S ⁽¹⁾		4,159	D	\$91.37 ⁽⁴⁾	4,000	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Amount or Number of Shares
Stock Option (Right to Buy)	\$8.44	06/01/2026		M ⁽¹⁾			3,998	(5)	06/06/2032	Common Stock	3,998	\$0	0	D	
Stock Option (Right to Buy)	\$17.88	06/01/2026		M ⁽¹⁾			6,908	(6)	01/23/2034	Common Stock	6,908	\$0	64,276	D	
Stock Option (Right to Buy)	\$21.77	06/01/2026		M ⁽¹⁾			6,249	(7)	05/22/2034	Common Stock	6,249	\$0	47,925	D	
Stock Option (Right to Buy)	\$22.07	06/01/2026		M ⁽¹⁾			9,375	(8)	02/03/2035	Common Stock	9,375	\$0	96,875	D	

Explanation of Responses:

- This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025.
- The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$89.17 to \$90.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$90.17 to \$91.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$91.17 to \$91.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

5. The shares of common stock underlying this stock option award vested as to 25% of the shares on April 25, 2023, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

6. The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

7. The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after May 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

8. The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

/s/ Adam Veness, as attorney-
in-fact for Simrat Randhawa 06/02/2026

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.